Aurinia Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Aurinia Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aurinia Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aurinia Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Aurinia Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20230381271A1 | Application | Protocol to minimize calcineurin inhibitor nephrotoxicity | A61K31/5377; A61K31/573; A61K38/13; A61P13/12; A61P37/06; G01N2800/347; G01N2800/52; G01N33/5308; G01N33/62; G01N33/6893; G01N33/70; G01N33/92 | November 30, 2023 |
| DK3634463T3 | Application | Forbedret protokol til behandling af lupus nephritis | A61K31/365; A61K31/5377; A61K31/573; A61K38/13; A61P13/12 | November 27, 2023 |
| EP4277646A1 | Application | Protokoll zur minimierung von calcineurininhibitor-nephrotoxizität | A61K31/5377; A61K31/573; A61K38/13; A61P13/12; A61P37/06; A61P39/00; G01N2800/245; G01N2800/347; G01N2800/52; G01N33/50; G01N33/5308; G01N33/62; G01N33/6893; G01N33/70; G01N33/92 | November 22, 2023 |
| FI3634463T3 | Grant | Improved protocol for treatment of lupus nephritis | A61K31/365; A61K38/13; A61K31/5377; A61K31/573; A61P13/12 | November 16, 2023 |
| KR1020230147069A | Application | 칼시뉴린 억제제 신독성을 최소화하는 프로토콜 | A61K31/5377; A61K31/573; A61K38/13; A61P13/12; A61P37/06; A61P39/00; G01N2800/245; G01N2800/347; G01N2800/52; G01N33/50; G01N33/5308; G01N33/62; G01N33/6893; G01N33/70; G01N33/92 | October 20, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer